New antibody takes aim at Hard-to-Treat cancers

NCT ID NCT07584954

Recruiting now Disease control Sponsor: Jun Zhou Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called IUAb190708, an antibody designed to attack cancer cells by targeting a protein called PD-L1. The study involves 90 adults with advanced or recurrent solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety and find the right dose, while also looking at whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IUAb190708, a cytotoxic antibody targeting PD-L1
What this could lead to: If it works, this could lead to a new treatment option for people with advanced solid tumors that haven't responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 90 participants, so the drug may not be effective or could have unexpected side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR CANCER SOLID TUMOR CANCER TREATMENT WITH IMMUNOTHERAPY

Contacts and locations

Locations

Anyang tumor hospital
RECRUITING

Anyang, Henan, China
Cancer hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, China
Fudan University Shanghai cancer center
RECRUITING

Shanghai, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, China
Shanghai Pulmonary hospital
RECRUITING

Shanghai, China
Shanghai Xinhua hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.